Publications 2024

Fuentes-Martín R, Ayuda-Durán P, Hanes R, Gallego-Yerga L, Wolterinck L, Enserink JM, Álvarez R, Peláez R (2024)
Promising anti-proliferative indolic benzenesulfonamides alter mechanisms with sulfonamide nitrogen substituents
Eur J Med Chem, 275, 116617
DOI 10.1016/j.ejmech.2024.116617, PubMed 38959729

Hanes R, Liu Y, Huang Z (2024)
Druggability Analysis of Protein Targets for Drug Discovery to Combat Listeria monocytogenes
Microorganisms, 12 (6)
DOI 10.3390/microorganisms12061073, PubMed 38930455

Publications 2023

Ayuda-Durán P, Hermansen JU, Giliberto M, Yin Y, Hanes R, Gordon S, Kuusanmäki H, Brodersen AM, Andersen AN, Taskén K, Wennerberg K, Enserink JM, Skånland SS (2023)
Standardized assays to monitor drug sensitivity in hematologic cancers
Cell Death Discov, 9 (1), 435
DOI 10.1038/s41420-023-01722-5, PubMed 38040674

Hanes R, Ayuda-Durán P, Rønneberg L, Nakken S, Hovig E, Zucknick M, Enserink JM (2023)
screenwerk: a modular tool for the design and analysis of drug combination screens
Bioinformatics, 39 (1)
DOI 10.1093/bioinformatics/btac840, PubMed 36573326

Hanes R, Zhang F, Huang Z (2023)
Protein Interaction Network Analysis to Investigate Stress Response, Virulence, and Antibiotic Resistance Mechanisms in Listeria monocytogenes
Microorganisms, 11 (4)
DOI 10.3390/microorganisms11040930, PubMed 37110353

Publications 2021

Grad I, Hanes R, Ayuda-Durán P, Kuijjer ML, Enserink JM, Meza-Zepeda LA, Myklebost O (2021)
Discovery of novel candidates for anti-liposarcoma therapies by medium-scale high-throughput drug screening
PLoS One, 16 (3), e0248140
DOI 10.1371/journal.pone.0248140, PubMed 33690666

Melvold K, Giliberto M, Karlsen L, Ayuda-Durán P, Hanes R, Holien T, Enserink J, Brown JR, Tjønnfjord GE, Taskén K, Skånland SS (2021)
Mcl-1 and Bcl-xL levels predict responsiveness to dual MEK/Bcl-2 inhibition in B-cell malignancies
Mol Oncol, 16 (5), 1153-1170
DOI 10.1002/1878-0261.13153, PubMed 34861096

Rønneberg L, Cremaschi A, Hanes R, Enserink JM, Zucknick M (2021)
bayesynergy: flexible Bayesian modelling of synergistic interaction effects in in vitro drug combination experiments
Brief Bioinform, 22 (6)
DOI 10.1093/bib/bbab251, PubMed 34308471

Publications 2019

Hanes R, Munthe E, Grad I, Han J, Karlsen I, McCormack E, Meza-Zepeda LA, Stratford EW, Myklebost O (2019)
Preclinical Evaluation of the Pan-FGFR Inhibitor LY2874455 in FRS2-Amplified Liposarcoma
Cells, 8 (2)
DOI 10.3390/cells8020189, PubMed 30795553

Publications 2017

Serguienko A, Hanes R, Grad I, Wang MY, Myklebost O, Munthe E (2017)
PP2A Regulatory Subunit B55γ is a Gatekeeper of Osteoblast Maturation and Lineage Maintenance
Stem Cells Dev, 26 (19), 1375-1383
DOI 10.1089/scd.2017.0129, PubMed 28805158

Publications 2016

Hanes R, Grad I, Lorenz S, Stratford EW, Munthe E, Reddy CC, Meza-Zepeda LA, Myklebost O (2016)
Preclinical evaluation of potential therapeutic targets in dedifferentiated liposarcoma
Oncotarget, 7 (34), 54583-54595
DOI 10.18632/oncotarget.10518, PubMed 27409346

Publications 2014

Magnussen S, Hadler-Olsen E, Latysheva N, Pirila E, Steigen SE, Hanes R, Salo T, Winberg JO, Uhlin-Hansen L, Svineng G (2014)
Tumour microenvironments induce expression of urokinase plasminogen activator receptor (uPAR) and concomitant activation of gelatinolytic enzymes
PLoS One, 9 (8), e105929
DOI 10.1371/journal.pone.0105929, PubMed 25157856

Publications 2011

Berdal M, Appelbom HI, Eikrem JH, Lund A, Busund LT, Hanes R, Seljelid R, Jenssen T (2011)
Aminated β-1,3-D-glucan has a dose-dependent effect on wound healing in diabetic db/db mice
Wound Repair Regen, 19 (5), 579-87
DOI 10.1111/j.1524-475X.2011.00715.x, PubMed 22092796